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Abstract
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a disabling autoim-
mune disorder of the peripheral nervous system (PNS). Intravenous immunoglobulins (IVIg)
are effective in CIDP, but the treatment response varies greatly between individual patients.
Understanding this interindividual variability and predicting the response to IVIg constitute
major clinical challenges in CIDP. We previously established intercellular adhesion molecule
(ICAM)-1 deficient non-obese diabetic (NOD) mice as a novel animal model of CIDP. Here,
we demonstrate that similar to human CIDP patients, ICAM-1 deficient NOD mice respond to
IVIg treatment by clinical and histological measures. Nerve magnetic resonance imaging and
histology demonstrated that IVIg ameliorates abnormalities preferentially in distal parts of the
sciatic nerve branches. The IVIg treatment response also featured great heterogeneity allow-
ing us to identify IVIg responders and non-responders. An increased production of interleukin
(IL)-17 positively predicted IVIg treatment responses. In human sural nerve biopsy sections,
high numbers of IL-17 producing cells were associated with younger age and shorter disease
duration. Thus, our novel animal model can be utilized to identify prognostic markers of treat-
ment responses in chronic inflammatory neuropathies and we identify IL-17 production as
one potential such prognostic marker.
Introduction
Inflammatory polyneuropathies constitute disabling autoimmune mediated disorders of the
peripheral nervous system (PNS). Acute and chronic variants have been described.The acute
Guillain-Barré syndrome (GBS) features rapid onset monophasic inflammation of the PNS [1,
2] and experimental autoimmune neuritis (EAN) serves as an animal model of its demyelinat-
ing variant [3]. Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)–the
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most common chronic inflammatory neuropathy–presents with slowly progressive or relaps-
ing remitting sensory and motor impairments due to immune cell infiltration of peripheral
nerves [4, 5]. Histologically, infiltrates of T lymphocytes and macrophages can be demon-
strated in the PNS of CIDP patients [6]. Glucocorticoids, plasma exchange and intravenous
immunoglobulins (IVIg) constitute established treatment options in CIDP, but do not benefit
all patients [7]. Significant and chronic disability is therefore frequent in CIDP [5]. Among the
available treatment options, IVIg features the most advantageous risk-to-benefit ratio and has
long-term positive effects [8], but its efficacy varies greatly between individual patients and its
mechanism of action in inflammatory neuropathies remains poorly defined. Identifying prog-
nostic markers of treatment responses in IVIg is clinically highly relevant.
Different modes of action have been described including effects on autoantibodies, Fc
immunoglobulin fragment receptors and on pro-inflammatory cytokines (reviewed in [9]).
Evidence supports that the various IVIg effects are mediated by its Fc portion as Fc fragment
preparations were sufficient to ameliorate rat EAN [10, 11]. Effects of IVIg on the expression
of the anti-inflammatory immunoglobulin receptor FcγRIIB on B cells has been reported in
CIDP patients [12]. IVIg ameliorates the acute EAN rat model [13]. The relevance of this find-
ing for CIDP is unknown and IVIg treatment has not been tested in chronic inflammatory neu-
ropathy animal models, which were only recently introduced. Such animal models of chronic
inflammatory neuropathies could help to extend our understanding of the IVIg effect [14].
We and others have previously reported, that mice of the autoimmune-prone non-obese
diabetic (NOD) strain with deficiency in the costimulatorymolecules B7-2 [15] and intercellu-
lar adhesion molecule (ICAM)-1 [16] spontaneously develop chronic inflammation and demy-
elination of peripheral nerves and constitute potential animal models of CIDP.
We here used ICAM-1-/-NODmice to further clarify IVIg effects in this chronic inflamma-
tory neuropathy model and identified production of interleukin (IL)-17 as one potential prog-
nostic marker predicting a beneficial effect of IVIg treatment. In sural nerve biopsy sections of




Animal experimentation was approved by the responsible state authorities (LANUVNRW)
under the approval reference number AZ 84–02.04.2011.A128. All animals were maintained
under specific pathogen free conditions. ICAM-1-/- mice on C57/BL6 background [17] were
backcrossed to NOD background (MHC haplotype H-2g7, Bomholtgard, Denmark) for 8 gen-
erations as previously described [18] and homozygous ICAM-1-/-NODmice were further
inbred. Homozygozity was confirmed by routine PCR from tail biopsies in randomly chosen
animals as previously described [17]. ICAM-1-/-NODmice were weekly analyzed for clinical
signs of neuropathy for the duration of the treatment in a blinded fashion by the same investi-
gator (S.C.). A modifiedEAN score [19] was applied: 0 no impairments, 1 reduced tone of the
tail, 2 limp tail, 3 absent righting reflex, 4 gait ataxia, 5 mild paraparesis, 6 moderate parapar-
esis, 7 severe paraparesis or paraplegia, 8 tetraparesis, 9 moribund, 10 death due to neuropathy.
IVIg Treatment and Study Design
A cohort of 60 female ICAM-1-/-NODmice with an average age of 227 days (median 229 days,
range 169–302 days) and an average clinical score of 0.69 (median 0.00, range 0–4) was
assessed by sciatic nerve electrophysiology (see below). Two littermate animals with clinical
scores greater than 4 were excluded. Animals were then randomized stratified first by nerve
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conduction velocities and second by clinical score into three cohorts (n = 20 each). Cohorts
either received intraperitoneal injections of 10 mg human albumin (100 μl of 100 mg/ml, com-
pany CSL Behring) three times per week (placebo group) or 10 mg human IVIg preparation
(100 μl of 100 mg/ml solution Kiovig, Baxter) three times per week (IVIg 3x group) or once per
week (IVIg 1x group) for nine weeks. The average clinical score in the last three weeks of treat-
ment was substracted from the average score in the first three weeks. Responders were defined
as animals with 1 score point increase or reduction of the clinical score during treatment.
Non-responders were defined as<1 score increase. Blood was taken from the animals before
treatment initiation by tail vein bleeding and intracellular cytokine staining of blood lympho-
cytes was performed (see below). At the end of the study, sciatic nerve electrophysiologywas
performed and animals were sacrifizedby cervical dislocation. Sciatic nerves were dissected
and one nerve was stored at -80°C for expression analysis and one fixed in 4% paraformalde-
hyde solution for histology. Spleens were dissected for immediate cytokine staining and prolif-
eration analysis.
Electrophysiology
Mouse sciatic nerve conduction properties were determined before treatment initiation and at
the end of the experiment as previously described [20]. Briefly, mice were anaesthetized using
brief inhalation narcosis with isofluran (Baxter), while constant body temperature was main-
tained using a heating plate connected to a rectal temperature sensor. Recording was per-
formed using a portable human electrophysiology device adapted to the setting (Dantec). Two
recording electrodeswere inserted into the small foot muscles to assess motor response. Two
monopolar stimulating electrodeswere placed dorsal of the ankle and at the sciatic notch
enclosing the sciatic nerve for distal and proximal stimulation, respectively. Stimulation was
performedwith increasing current until supramaximal stimulation was achieved.Maximum
compoundmuscle action potential (CMAP) amplitude voltage (mV) was recorded. Nerve con-
duction velocity (NCV, m/s) was calculated as the quotient between the distance and the differ-
ence of motor latencies between proximal and distal stimulation. Average values were
calculated from two independent recordings per animal.
Histology
Fixed sciatic nerves from randomly chosen animals from the placebo (n = 8) and IVIg 3x
group (n = 10) were cut into proximal, mid and distal pieces and paraffin embedded.Nerves
were cut into 7 μm sections on a standard microtome and haematoxylin-eosin (HE) stained
following standard protocols and dehydrated and mounted in xylene basedmedium (Merck).
Entire sciatic nerve sections at proximal, mid and distal level were photographed in parallel at
40x magnification using a standard microscope (Zeiss). Photographs were merged and con-
verted to binary (threshold 80) using Photohop CS3 (Adobe). The number of cell nuclei was
automatically quantified using the Analyze Particle function (size = 50–400 circularity = 0.40–
1.00) of ImageJ (v1.45, NIH). The endoneural area was measured and the nuclear density
(nuclei / mm2) was calculated for each section image. To verify automatic quantification, nuclei
were manually counted in six randomly selected images using the cell counter plug-in of Ima-
geJ. Values closely correlated with automatic values. Luxol Fast Blue (LFB) staining was per-
formed by deparaffinizing sciatic nerve sections, staining with 0.1% Luxol Blue for 18 hours at
57°C, differentiating with 0.1% lithium carbonate for one minute and mounting the sections.
Photos of the stained sections were taken, converted to grayscale and the relative darkness (0
white, 255 black) of the endoneural area was quantified with Image J.
Response to IVIg in Chronic Neuritis
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Cell Preparation and Flow Cytometry
Intracellular cytokine staining was performed using bloodmononuclear cells at the beginning
and splenocytes after completion of the study. Proliferation analyses were performed using
splenocytes at the end of the study.
Spleens were passed through a 40 μm cell strainer followed by erythrocyte lysis (both BD
Biosciences). For proliferation analysis, splenocytes were cultured in the presence of syngenic
mouse sciatic nerve homogenisate (50 mg/ml) or stimulated using soluble antibody against
CD3 (1μg/ml, clone 145-2C11, from BD Pharmingen) and CD28 (0.5 μg/ml, clone PV-1, from
Abcam). 2x105 splenocytes were maintained in 96-well plates for 96 hours at 37°C in a humidi-
fied CO2 incubator. 3H-Thymidin (Hartmann Analytic) was added for the last 24 hours and
proliferation was assessed in quadruplicate wells by measuring 3H-Thymidine incorporation.
Stimulatory indices were calculated by dividing counts per minute (CPM) of each well by the
average CPM of non-stimulated wells.
Blood taken by tail vein bleeding was collected in 75 μl hematocrit capillaries (Radiometer
Clinical Aps) and transferred into 1ml of PBS/1%FCS/10mMEDTA solution followed by
erythrocyte lysis. For intracellular cytokine staining, blood or spleen cells were cultured for 4
hours in 96-well plates at 37°C in a humidifiedCO2 incubator in the presence of PMA (10 ng/
ml), ionomycin (1 μg/ml) and BD Golgistop. Cells were subsequently stained for cell surface
CD4 (clone L3T4), CD3 (clone 145-2C11) and intracellular IL-17 (clone TC11-18H10) using
the intracellular cytokine staining buffer set following the manufacturer’s protocol (all from
BD Biosciences). Flow cytometrywas performed using a FACSCanto II flow cytometer (BD
Biosciences).
Magentic Resonance Imaging
Magnetic resonance imaging (MRI) in mice was performed during inhalation narcosis with
isofluran (4% in O2) using a 9.4T magnetic resonance (MR) scanner (Biospec 94/20, BRUKER,
Ettlingen). A circular polarized cryoprobe was used in Tx/Rx setting.We acquired T2w images
using a RARE (TR/TE: 2859/42ms, matrix: 320 x 320, pixel spacing: 0.0625 x 0.0625mm, slice
thickness: 0.3mm, slices: 20, time: 13min 20sec) based sequence. Sciatic nerves were segmented
and the normalized T2 signal was measured using ImageJ (v1.47, NIH) by defining the inten-
sity of surroundingmuscle tissue as 1.0 and calculating the relative T2 signal intensity of the
sciatic nerve.
Data Acquisition and Analysis
All flow cytometry data were analyzed using FlowJo software (v7.2.5 TreeStar). Data were sta-
tistically analyzed using GraphPadPrism 5.0 (GraphPad Software). TheWilcoxon-Mann-
Whitney and Student’s t-test for unrelated samples were used to test for statistically significant
differences of non-Gaussian and Gaussian distributed data, respectively. Differences were con-
sidered significant at p-values< 0.05.
Results
IVIg Treatment Ameliorates Chronic Inflammatory Neuropathy in ICAM-
1-/-NOD Mice
We had previously established ICAM-1-/-NODmice as a novel animal model of human CIDP
[16]. We now asked whether this model could also help to improve our understanding of CIDP
treatments and we therefore tested whether IVIg are effective in ICAM-1-/-NODmice.We ran-
domized a large cohort (n = 60) of pre-symptomatic and mildly affected ICAM-1-/-NODmice
Response to IVIg in Chronic Neuritis
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(mean clinical score 0.59, mean age 7.6 months) into three matched groups (n = 20 each) strati-
fied first to their NCV and second to their clinical score to receive intraperitoneal injections of
either once weekly IVIg (IVIg 1x; mean score 0.67, mean age 7.4 months), or three times
weekly IVIg (IVIg 3x; mean score 0.53, mean age 7.4 months) or three times weekly albumin
(placebo;mean score 0.56, mean age 7.9 months). The randomized groups did not differ before
treatment (S1 Table). Cytokine production by peripheral blood CD3+ T cells was quantified by
intracellular cytokine staining before the start of IVIg treatment (see below).
As expected in this chronically progressive model, the average clinical score continuously
increased in placebo treated mice (Fig 1A). In comparison to these controls, IVIg 3x treated
animals developed a significantly lower disease severity (Fig 1A) after six, eight and nine weeks
of treatment. The difference between placebo and IVIg 3x treated mice was most pronounced
at the end of the observation (Fig 1B). IVIg 1x treatment generated a similar trend, but the dif-
ference did not reach statistical significance (Fig 1A and 1B). We next analyzed the incidence
of any clinically detectable impairments. Cumulative neuritis incidence in the placebo group
increased to 91% in contrast to 69% in the IVIg 3x group indicating a reduction by IVIg 3x
treatment although the survival analysis did not reach significance (Fig 1C). Of note, the
response to IVIg treatment was highly heterogenous and clinical scores were negatively
Fig 1. IVIg ameliorates chronic neuritis in ICAM-1-/-NOD mice. (A) We randomized a cohort (n = 60) of pre-symptomatic ICAM-1-/-NOD mice into three
score-matched groups (n = 20 each) to receive either once weekly IVIg (IVIg 1x), three times weekly IVIg (IVIg 3x) or three times weekly albumin (placebo)
treatment. The treatment was performed for 9 weeks in all animals and clinical scoring was performed weekly. (B) The average score at the end of the
observation period in the placebo (pla) and IVIg treatment groups is shown. (C) The proportion of mice with clinically detectable impairment was quantified
during treatment. ns not significant. (D) The compound muscle action potential (CMAP) amplitude and nerve conduction velocity (NCV) was measured after
9 weeks of treatment and correlated with the clinical score on the same date. (E) Sciatic nerve electrophysiology was performed by stimulating the sciatic
nerve with needle electrodes at the gluteal (proximal) and ankle (distal) level and recording CMAPs with a needle electrode from the small foot muscles.
Representative plots from all treatment groups are shown. (F) Sciatic nerve paraffin sections were H&E stained. Scale bar represents 100 μm. (G) The
cellular density per section was quantified. n = 10 per group. Pla placebo.
doi:10.1371/journal.pone.0164099.g001
Response to IVIg in Chronic Neuritis
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correlated with NCV (r = - 0.49, p< 0.001) and CMAP amplitudes (r = - 0.54, p< 0.001) (Fig
1D). Electrophysiological abnormalities were generally more pronounced in placebo than in
IVIg treated animals (Fig 1E) but differences did not reach statistical significance (data not
shown), which may be due to high technical variability. We next histologically quantified neu-
ritis severity and found that cellular infiltration into the PNS was reduced by IVIg 3x treatment
in comparison to placebo (Fig 1F and 1G). Cellular infiltration negatively correlated with NCV
and CMAP amplitudes and positively correlated with clinical scores (S1 Fig) argueing for the
adequancy of this histological quantification of nerve inflammation. In summary, IVIg 3x
treatment thus ameliorates the average severity and suppresses the manifestation of chronic
murine neuritis in ICAM-1-/-NODmice.
Nerve MRI in Mice Allows Quantifying Treatment Effects in ICAM-
1-/-NOD Mice
Nerve histology is not feasible for longitudinal studies and we intended to establish an alterna-
tive, non-invasive quantification of PNS inflammation in mice during treatment. We therefore
performed 9.4T sciatic nerveMRI in NODmice and treated and untreated ICAM-1-/-NOD
mice. The sciatic nerve could be readily identified from the gluteal to the thigh region on T2
weightedMRI images. We found that T2 intensity was higher in ICAM-1-/-NODmice than in
NOD control mice and correlated with the severity of clinical and electrophysiological abnor-
malities (Fig 2A). We quantified this observation by first normalizing sciatic nerve T2 intensity
against the surroundingmuscle tissue and second normalizing this relative T2 intensity of
ICAM-1-/-NOD sciatic nerves against NOD controls.
We then segmented the sciatic nerve into 17 individual sections from proximal (parallel to
the first caudal vertebra; 0–8) to distal (parallel to the second caudal vertebra; 9–17) and found
that the normalized T2 signal was higher in ICAM-1-/-NODmice over the entire length of cov-
erage. This higher T2 signal in ICAM-1-/-NOD nerves was more pronounced in distal parts of
the sciatic nerve (Fig 2B). Interestingly, the normalized T2 intensity was unchanged by IVIg
treatment in proximal sections whereas IVIg 3x treatment preferentially reduced distal T2
hyperintensities (Fig 2B). To correlate MRI findings with histology we stained for myelin (S2A
Fig) and cell content (S2B Fig) at different sites of the sciatic nerve of ICAM-1-/-NODmice.
Both demyelination and cellular infiltration correlated well with clinical and electrophysiologi-
cal parameters (S2 Table) and distal nerve parts were more severely affected. Similar to MRI,
histology thus shows a proximal-to-distal gradient of abnormailities in our model. This indi-
cates that nerveMRI is a feasible, non-invasive measure of PNS inflammation and inflamma-
tory demyelination in our murine model of chronic neuritis and that IVIg treatment effects
can be monitored by nerveMRI. IVIg may act preferentially in distal parts of the PNS.
High IL-17 Production in Blood T Cells Predicts Treatment Response to
IVIg
We next tested how IVIg 3x treatment influenced the spontaneous autoimmune response
against PNS myelin we had previously identified in ICAM-1-/-NODmice [16]. We found that
both polycloncal and myelin induced proliferation of splenic lymphocytes was reduced by IVIg
3x treatment (Fig 3A). We had previously observeddevelopment of neuritis in ICAM-1-/-NOD
mice to be associated with an increased production of pro-inflammatory IL-17 [16]. We there-
fore performed intracellular cytokine staining of splenic lymphocytes to study the mechanism
by which IVIg treatment ameliorated chronic neuritis. Surprisingly, IVIg 3x treatment did not
alter IL-17 production by T lymphocytes (Fig 3B) indicating that effects of IVIg treatment in
peripheral lymphoid organs are primarily IL-17-independent.
Response to IVIg in Chronic Neuritis
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Predicting the individual response to IVIg in CIDP is clinically highly relevant, but no pre-
dictive biomarkers have been identified.We therefore next addressed whether our animal
model could also be used to identify such prognostic biomarkers by comparing pre-treatment
cytokine production with the treatment response (Fig 3C). The percentage of IL-17 producing
T cells in the peripheral blood before IVIg treatment negatively correlated with the change in
clinical score during treatment (Fig 3D) while the percentage of cytokine-producing cells after
treatment did not correlate (S1B Fig). High levels of IL-17 producing T cells were thus
Fig 2. Sciatic nerve MRI detects abnormalities and IVIg effects in ICAM-1-/-NOD mice. (A) Untreated, pre-diabetic NOD mice without
clinical impairments (n = 3), IVIg 3x treated ICAM-1-/-NOD mice (n = 6), and placebo treated ICAM-1-/-NOD mice (n = 4) were analyzed in a
9.4T small animal MRI. Anesthesia was performed with 4% isofluran in O2 during imaging. A circular polarized cryoprobe was used in Tx/Rx
setting and we acquired T2w images. Sciatic nerves were segmented and the T2 signal was normalized to NOD controls using ImageJ. (B)
The sciatic nerve was manually outlined on consecutive image slices from proximal to distal anatomical location. The T2 signal was
normalized against surrounding muscle tissue and then normalized using NOD nerve intensity as reference. The relative T2 intensity of one
representative placebo treated ICAM-1-/-NOD mouse (red circles) and one IVIg 3x treated ICAM-1-/-NOD mouse (blue circles) was plotted
against anatomical position.
doi:10.1371/journal.pone.0164099.g002
Response to IVIg in Chronic Neuritis
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Fig 3. Pre-treatment IL-17 production by blood T cells predicts IVIg response in ICAM-1-/-NOD mice. (A) Splenocytes
were extracted from placebo (Pla) and IVIg 3x treated mice (n = 5 per group) after 9 weeks of treatment and stimulated in the
presence of soluble anti-CD3 (1μg/ml) and anti-CD28 (0.5 μg/ml) antibodies (polyclonal) or mouse sciatic nerve homogenisate
(PNS; 50 mg/ml) for 96 hours. Proliferation was measured by Thymidin incorporation in the last 24 hours and calculated as fold
non-stimulated wells. (B) Peripheral blood was collected before (left panel) from placebo (Pla) and IVIg 3x treated mice (n = 20
per group), stimulated for 4 hours with PMA/Ionomycin/Golgi Transport Inhibitor and stained for intracellular IL-17. Splenocytes
Response to IVIg in Chronic Neuritis
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associated with a beneficial response to IVIg in ICAM-1-/-NODmice. This suggests that IL-17
could serve as a predictor of IVIg treatment responses in chronic neuritis.
We next addressed how IVIg affected IL-17 production in the PNS and therefore stained
sections of the sciatic nerve at proximal, middle, and distal levels for IL-17. We found that the
density of IL-17+ cells was significantly decreased in mice treated with 3x IVIg at middle and
distal levels of the sciatic nerve (Fig 3E). This observation indicates that IVIg treatment reduces
the production of pro-inflammatory IL-17 in the peripheral nerves of ICAM-1-/-NODmice.
Taken together our data suggest that IL-17 production in the blood predicts subsequent treat-
ment responses to IVIg (Fig 3D) and that IVIg does not change IL-17 production in secondary
lymphoid organs (Fig 3B), but may decrease IL-17 production locally in the inflamed PNS
(Fig 3E).
IL-17 Production Is Elevated in Sural Nerve Biopsies of Early Stage
CIDP Patients
We next sought to examine the relevance of IL-17 in human CIDP. Data regarding IL-17 pro-
ducing T cells in CIDP are limited [21–23]. First, we histologically analyzed IL-17 production
in the PNS of CIDP patients and found IL-17 producing T cells sural nerve biopsies of CIDP
patients similar to sciatic nerves of ICAM-1-/-NODmice (Fig 4A). We therefore asked whether
increased IL-17 production in ICAM-1-/-NODmice was paralleled in human chronic inflam-
matory neuropathies. We took an immunohistochemical approach to study IL-17 production
at the site of inflammatory injury in sural nerve biopsy cross-sections of CIDP patients. When
we quantified this, we found a statistically marginally non-significant trend (p = 0.0622)
towards increased endoneural IL-17+ cells in sural nerve biopsy tissue from CIDP patients
compared to non-CIDP controls (Fig 4B, S3 Table). Of note, the presence of IL-17+ cells
dichotomized CIDP patients into samples with (IL-17-CIDP) or without (non-IL-17-CIDP)
presence of IL-17+ cells in the PNS when we chose an arbitrary threshold defined by our con-
trol patients (Fig 4B).
We next compared the clinical and electrophysiological characteristics of IL-17-CIDP and
non-IL-17-CIDP patients (S3 Table). We found that IL-17-CIDP patients were significantly
younger (Fig 4C), had a trend towards shorter self-reported disease duration (Fig 4D) and
higher tibial nerve CMAP amplitudes (Fig 4E) than non-IL-17-CIDP patients, while histologi-
cal parameters did not differ (S3 Table). This indicates that IL-17 may be involved in the local
immune response in the PNS in CIDP. High IL-17 production could thus be associated with
high disease activity that is preferentially reduced by IVIg treatment and such patients may
thus respond better to IVIg therapy.
Discussion
We had previously established ICAM-1-/-NODmice as a novel animal model of human CIDP.
Here, we used this model to make important discoveries in chronic neuritis. First, IVIg treat-
ment ameliorates chronic neuritis in ICAM-1-/-NODmice and this treatment response features
great heterogeneity. This opens up an angle to experimentally study this heterogeneity. Second,
were extracted from treated mice after treatment (right panel) and stained for intracellular IL-17. The proportion of IL-17+ of CD3
+ cells before (left panel) and after (right panel) treatment was calculated. (C) Schematic representation of the prognostic
analysis. Responders were defined as1 average score increase during treatment. (D) The proportion of IL-17+ CD3+ cells was
plotted against the change of score during IVIg 3x treatment. (E) Paraffin sections were generated at different levels of the sciatic
nerve at the sciatic notch (proximal, left panel), at mid thigh (mid, middle panel), at the sciatic trifurcation (distal, right panel) were
stained for IL-17, IL-17+ cells were counted and the density of IL-17+ cells per area was calculated. ns not significant.
doi:10.1371/journal.pone.0164099.g003
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nerveMRI is feasible and allows quantifying treatment-dependent nerve abnormalities in a
rodent model of chronic nerve inflammation. NerveMRI may thus also allow tracking treat-
ment effects in chronic inflammatory neuropathies. Third, prospectively quantified IL-17 pro-
duction by blood T cells predicts the response to IVIg treatment in ICAM-1-/-NODmice and
intraneural IL-17 production is enhanced preferentially in early stage human CIDP patients.
Fig 4. The intraneural presence of IL-17 producing cells dichotomizes CIDP patients. (A) Paraffin sections
of sciatic nerves of ICAM-1-/-NOD mice (top panel) and representative sural nerve biopsies of CIDP patients
(bottom panel) were stained against CD3 (green signal) and IL-17 (red signal) and counterstained with DAPI (blue
signal). Scale bars represent 20 μm. (B) The density of endoneural IL-17+ cells in human sural nerve biopsies was
compared between controls (squares) and CIDP patients (circles and triangles) by DAB based IL-17 staining.
CIDP samples were arbitrarily divided into having high (triangles, IL-17-CIDP) or low (circles, non-IL-17-CIDP)
densities of IL-17+ cells. (C-E) Clinical features age (C), disease duration before biopsy (D) and tibial nerve CMAP
amplitudes (E) were retrospectively compared between IL-17-CIDP and non-IL-17-CIDP patients.
doi:10.1371/journal.pone.0164099.g004
Response to IVIg in Chronic Neuritis
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These findings support the adequacy of the ICAM-1-/-NODmodel and set the stage for subse-
quent studies directed at identifying prognostic markers of the highly heterogenous IVIg treat-
ment response in CIDP.
MRI abnormalities correlated with clinical impairments in our model and were most pro-
nounced in distal parts of the sciatic nerve whileMRI demonstrated IVIg treatment effects
most prominently in distal parts of the sciatic nerve.We thus show that nerve T2 signal is a
usefulmarker to monitor inflammatory neuropathy in mice and can also be used to monitor
and localize effects of IVIg treatment.
Peripheral nerveMRI has been used to study many different aspects of peripheral nerve dis-
eases (reviewed in [24]). Recent studies have utilized contrast enhancement agents to visualize
different cellular components and aspects of nerve damage and regeneration [25–28]. More
recent studies have also used the diffusion tensor imaging (DTI) technique to assess axonal
integrity and regeneration by MRI [29].
Several studies have reported T2 signal hyperintensities of the affected peripheral nerve but
also reported that MRI signal alterations cannot be directly equated with one type of lesion or a
primary cause of disease [30]. It has been speculated that T2 hyperintensities reflect axonal injury
and persistent signal abnormailities may even allow to detect inadequate axonal regeneration [24,
31]. T2 hyperintensities may thus reflect axonal degeneration and may in fact even allow assess-
ing axonal regeneration. Acute immune-mediated and chronic inherited demyelination on the
other hand did not result in obvious T2 hyperintensities in another study [32]. We therefore
speculate that the T2 hyperintensities we observed, reflect ongoing axonal degeneration. In our
animal model of CIDP, cellular infiltration, inflammatory demyelination, and axonal degenera-
tion are closely linked [16] because all abnormalities result from T cell autoreactivity against the
PNS. The ICAM-1-/-NODmouse is thus poorly suited to dissect the relative contribution of
demyelination, axonal loss and cellular infiltration in causing specificMRI alterations. Perform-
ing nerveMRI in this model of CIDP, however, does allowmonitoring treatment effects and pre-
clinically testing and localizing the primariy site of action of such treatments.
Other studies have reported an increase in IL-17 production in CIDP. The percentage of
peripheral Th17 cells and IL-17 plasma levels were increased in human CIDP patients with
active disease [33]. Concentrations of IL-17 and IL-6, which induces IL-17, were also reported
to be increased in the cerebrospinal fluid of CIDP patients [22]. Others reported an increased
IL-17 production by bloodmononuclear cells in CIDP patients, although this was not specific
for this cytokine and IFN-γ levels were also increased [21]. Thus, our findings demonstrating
increased intraneural IL-17 production in CIDP are in accordance with previous studies and
IL-17 may constitute a future prognostic marker of IVIg treatment response.
IVIg is a preparation of human polyclonal IgG obtained from plasma of several thousands
of healthy donors [34] and has demonstrated therapeutic efficacy in CIDP [35]. However, the
mechanism of action of IVIg remains incompletely understood and probably cannot be attrib-
uted to one specificmechanism of action. Potential mechanisms of IVIg include: anti-idiotype
effects, inhibition of the complement pathway, Fc receptor modulation on macrophages and
other effector cells, suppression of pathogenic cytokines, and effects on cell migration and
direct effect on remyelination (reviewed in [34, 36]). Human IVIg have previously demon-
strated efficacy in murine models of inflammatory neuropathies [11, 13] and in murine models
of other diseases such as Alzheimer’s disease and rheumatoid arthritis [37, 38]. The IVIg effects
are thus at least partly species independent and have been attributed to the Fc portion of the
immunoglobulins (reviewed in [39]). This supports our approach of utilizing human IVIg
preparations to treat a murine autoimmune diseasemodel. In addition, our study was specifi-
cally designed to identify prognostic markers of the IVIg treatment response in CIDP and we
identify IL-17 as one potential prognostic factor in chronic inflammatory neuropathies.
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Our study has certain technical limitations: Despite stratification by both pre-treatment NCV
and clinical score we observeda considerable degree of inter-individual variability in clinical
score and response to treatment. The differences between treatment groups were thus not very
pronounced. IVIg treatment also did not significantly change electrophysiologymeasures after
treatment (data not shown). Interestingly, electrophysiologymeasures were also not significantly
altered by IVIg treatment in human CIDP patients [35] although electrophysiology correlated
with clinical impairments [40]. We speculate that more clearly demonstrating IVIg efficacymay
require a longer treatment duration or further increase of IVIg dosage. An alternative approach
could be to synchronize the disease onset of chronic neuritis by adoptive transfer into immuno-
deficient hosts as we have previously reported [41] and treating the recipients with IVIg.
Prospectively collecting samples from early stage human CIDP patients during IVIg treat-
ment is challenging. CIDP diagnosis is often made with considerable delay and due to its cost,
IVIg is often used as a second-line treatment. This prognostic aspect can be addressed with rel-
ative ease in our model. Compared to human patients, a relatively homogenous cohort of mice
can be treated even before the onset of severe clinical impairments. Our attempt to identify a
prognostic biomarker of treatment response to IVIg was pre-biased by our previous findings
that IL-17 production is enhanced in ICAM-1-/-NODmice. It will be an important future
direction of study to perform prospective, un-biased, genome-wide expression analyses in
IVIg-treated ICAM-1-/-NODmice.
In conclusion, we here utilized a previously established model of chronic inflammatory neu-
ropathies to identify a potential prognostic biomarker and to establish nerveMRI as a non-
invasive tool for treatment monitoring, that sets the stage for future studies.
Supporting Information
S1 Fig. Cellularnerve infiltration correlates with electrophysiologicaland clinicalmeasures
of neuritis. (A) Sciatic nerve electrophysiologywas performed and nerve conduction velocity
(NCV) and compoundmuscle action potential (CMAP) amplitudes of the right sciatic nerve
were measured after 9 weeks of IVIg treatment. Sciatic nerve paraffin sections were H&E
stained and the cellular density per sectionwas quantified. The NCV (top left panel) and
CMAP amplitude (top right panel) and the clinical score after treatment (bottom panel) were
plotted against the cellular density per sciatic nerve section in each animal. Pearson’s correla-
tion coefficient and significance level are indicated in each panel. (B) Splenocytes were
extracted from treated mice after treatment, stimulated for 4 hours with PMA/Ionomycin/
Golgi Transport Inhibitor, and stained for intracellular IL-17. The proportion of IL-17+ CD3
+ cells in the blood after IVIg was plotted against the change of score during IVIg 3x treatment.
(PDF)
S2 Fig. Demyelination and cellular infiltration show a proximal-to-distal increase in
ICAM-1-/-NOD mice. (A) Sciatic nerve sections from proximal, mid, and distal parts of the
sciatic nerve of NOD and ICAM-1-/-NODmice were stained with Luxol Fast Blue (LFB) and
the intraneural LFB staining intensity was quantified (0 white– 255 black). (B) Sciatic nerve
sections described in A were H&E stained and the cellular density was quantified.
(PDF)
S1 Table. Characteristicsof randomized ICAM-1-/-NOD groups before IVIg treatment. SD
standard deviation,NCV nerve conduction velocity.
(XLS)
S2 Table. Clinical, electrophysiologicaland histopathological features of ICAM-1-/-NOD
mice analyzedby bothMRI and histology in the present study. LFB Luxol Fast Blue, CMAP
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compoundmuscle action potential,NCV nerve conduction velocity.
(XLS)
S3 Table. Clinical, electrophysiologicaland histopathological features of CIDP and control
patients analyzed in the study. endo IL-17 density of endoneural IL-17+ cells (cells per mm2),
epi IL-17 density of epineural IL-17+ cells (cells per mm2),mmale, f female, PNP polyneuropa-
thy, HNPP hereditary neuropathy with liability to pressury palsies, Lyme Lyme borreliosis, sens
sensory symptoms, dur duration of disease before sural nerve biopsy (years),motmotor symp-
toms, recur recurrent, progr progressive, resp response, tib tibial nerve, sur sural nerve, amp
amplitude, ncv nerve conduction velocity, csf prot cerebrospinal fluid protein concentration
(mg/dl), csf cell cerebrospinal fluid cell count (/μl), ax axonal, demy demyelinating, T endo
endoneural T cell density (cells per mm2), T epi epineural T cell density (cells per mm2), av
average, p p-value calculated in Student’s t-test for unrelated samples.
(XLS)
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